- Home
- TLPH vs KZIA Comparison
TLPH vs KZIA Comparison
Compare TLPH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- KZIA
- Stock Information
- Founded
- TLPH 2005
- KZIA 1994
- Country
- TLPH United States
- KZIA Australia
- Employees
- TLPH N/A
- KZIA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- KZIA Health Care
- Exchange
- TLPH Nasdaq
- KZIA Nasdaq
- Market Cap
- TLPH 11.1M
- KZIA 9.0M
- IPO Year
- TLPH 2011
- KZIA 1999
- Fundamental
- Price
- TLPH $0.98
- KZIA $8.01
- Analyst Decision
- TLPH Strong Buy
- KZIA Strong Buy
- Analyst Count
- TLPH 1
- KZIA 2
- Target Price
- TLPH $6.00
- KZIA $14.00
- AVG Volume (30 Days)
- TLPH 7.3M
- KZIA 137.6K
- Earning Date
- TLPH 11-12-2025
- KZIA 11-14-2025
- Dividend Yield
- TLPH N/A
- KZIA N/A
- EPS Growth
- TLPH N/A
- KZIA N/A
- EPS
- TLPH N/A
- KZIA N/A
- Revenue
- TLPH $27,000.00
- KZIA $1,549,158.00
- Revenue This Year
- TLPH N/A
- KZIA N/A
- Revenue Next Year
- TLPH $14,533.26
- KZIA $49.25
- P/E Ratio
- TLPH N/A
- KZIA N/A
- Revenue Growth
- TLPH N/A
- KZIA 248983.08
- 52 Week Low
- TLPH $0.38
- KZIA $2.86
- 52 Week High
- TLPH $1.20
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- TLPH 58.69
- KZIA 49.61
- Support Level
- TLPH N/A
- KZIA $7.60
- Resistance Level
- TLPH $1.20
- KZIA $8.88
- Average True Range (ATR)
- TLPH 0.12
- KZIA 0.53
- MACD
- TLPH 0.01
- KZIA 0.04
- Stochastic Oscillator
- TLPH 81.67
- KZIA 36.03
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.